Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

741
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
741
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

669
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
669
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

629
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
629
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

935
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
935
Acne Infection01:27

Acne Infection

47
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
47

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Refractory Pruritus Secondary to Linear IgA Bullous Dermatosis Treated Successfully With Nemolizumab: A Case Report.

Journal of drugs in dermatology : JDD·2025
Same author

Mechanism of Action of Brodalumab May Correlate With Efficacy in Patients With Inflammatory Skin Diseases.

Journal of drugs in dermatology : JDD·2023
Same author

Successful Management of Erythema Dyschromicum Perstans Following Topical Ruxolitinib Therapy.

Journal of drugs in dermatology : JDD·2023
Same author

An Investigator-Initiated Trial of a Polymeric Emulsion of Halobetasol Propionate and Tazarotene in the Treatment of Palmoplantar Psoriasis.

Journal of drugs in dermatology : JDD·2023
Same author

International Dermatology Outcome Measures (IDEOM): Report from the 2021 Annual Meeting.

Journal of drugs in dermatology : JDD·2022
Same author

Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.

American journal of clinical dermatology·2022

Related Experiment Video

Updated: Mar 30, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.7K

Secukinumab for treating plaque psoriasis.

Brooke Rothstein1, Alice Gottlieb1

  • 1a Department of Dermatology , Tufts Medical Center, Tufts University School of Medicine , 800 Washington St, #114, Boston , MA 02111 , USA.

Expert Opinion on Biological Therapy
|November 19, 2015
PubMed
Summary

Secukinumab, an IL-17 inhibitor, offers improved skin clearance and quality of life for plaque psoriasis patients. This biologic provides a new option when other treatments fail, with a favorable side-effect profile.

Keywords:
Th17interleukin (IL)-17plaque psoriasispsoriatic arthritissecukinumab

More Related Videos

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

1.0K

Related Experiment Videos

Last Updated: Mar 30, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.7K
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

1.0K

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Plaque psoriasis is a chronic inflammatory condition impacting physical and psychological well-being.
  • Limited biologic options previously existed, primarily TNF-α inhibitors and IL-12/23 inhibitors.
  • Newer biologics targeting IL-17A show high clinical efficacy in psoriasis management.

Purpose of the Study:

  • To review the pharmacology, efficacy, and safety of secukinumab.
  • To discuss the role of IL-17 inhibitors in plaque psoriasis treatment.
  • To evaluate secukinumab as a novel therapeutic option.

Main Methods:

  • Comprehensive literature review.
  • Analysis of clinical trial data for secukinumab and other IL-17 blockers.
  • Evaluation of safety and efficacy profiles.

Main Results:

  • Secukinumab targets the pro-inflammatory IL-17A cytokine.
  • It has demonstrated significant clinical efficacy in moderate-to-severe plaque psoriasis.
  • Offers improved skin clearance and health-related quality of life.

Conclusions:

  • Secukinumab represents a significant advancement in biologic therapy for plaque psoriasis.
  • It provides an effective alternative for patients experiencing loss of response to other biologics.
  • The drug presents a favorable side-effect profile, enhancing patient care.